医学
改良兰金量表
冲程(发动机)
随机对照试验
荟萃分析
优势比
脑出血
内科学
溶栓
临床试验
物理疗法
心肌梗塞
缺血性中风
蛛网膜下腔出血
缺血
工程类
机械工程
作者
Tudor Jovin,Raul G Nogueira,Maarten G. Lansberg,Andrew M. Demchuk,Sheila Cristina Ouriques Martins,J Mocco,Marc Ribó,Ashutosh P. Jadhav,Santiago Ortega‐Gutiérrez,Michael D. Hill,Fabrício Oliveira Lima,Diogo C Haussen,Scott Brown,Mayank Goyal,Adnan H. Siddiqui,Jeremy J. Heit,Bijoy K. Menon,Stephanie Kemp,R Budzik,Xabier Urra,Michael P. Marks,Vincent Costalat,David S. Liebeskind,Gregory W. Albers
出处
期刊:The Lancet
[Elsevier]
日期:2021-11-11
卷期号:399 (10321): 249-258
被引量:207
标识
DOI:10.1016/s0140-6736(21)01341-6
摘要
Background Trials examining the benefit of thrombectomy in anterior circulation proximal large vessel occlusion stroke have enrolled patients considered to have salvageable brain tissue, who were randomly assigned beyond 6 h and (depending on study protocol) up to 24 h from time last seen well. We aimed to estimate the benefit of thrombectomy overall and in prespecified subgroups through individual patient data meta-analysis. Methods We did a systematic review and individual patient data meta-analysis between Jan 1, 2010, and March 1, 2021, of randomised controlled trials of endovascular stroke therapy. In the Analysis Of Pooled Data From Randomized Studies Of Thrombectomy More Than 6 Hours After Last Known Well (AURORA) collaboration, the primary outcome was disability on the modified Rankin Scale (mRS) at 90 days, analysed by ordinal logistic regression. Key safety outcomes were symptomatic intracerebral haemorrhage and mortality within 90 days. Findings Patient level data from 505 individuals (n=266 intervention, n=239 control; mean age 68·6 years [SD 13·7], 259 [51·3%] women) were included from six trials that met inclusion criteria of 17 screened published randomised trials. Primary outcome analysis showed a benefit of thrombectomy with an unadjusted common odds ratio (OR) of 2·42 (95% CI 1·76–3·33; p<0·0001) and an adjusted common OR (for age, gender, baseline stroke severity, extent of infarction on baseline head CT, and time from onset to random assignment) of 2·54 (1·83–3·54; p<0·0001). Thrombectomy was associated with higher rates of independence in activities of daily living (mRS 0–2) than best medical therapy alone (122 [45·9%] of 266 vs 46 [19·3%] of 238; p<0·0001). No significant difference between intervention and control groups was found when analysing either 90-day mortality (44 [16·5%] of 266 vs 46 [19·3%] of 238) or symptomatic intracerebral haemorrhage (14 [5·3%] of 266 vs eight [3·3%] of 239). No heterogeneity of treatment effect was noted across subgroups defined by age, gender, baseline stroke severity, vessel occlusion site, baseline Alberta Stroke Program Early CT Score, and mode of presentation; treatment effect was stronger in patients randomly assigned within 12–24 h (common OR 5·86 [95% CI 3·14–10·94]) than those randomly assigned within 6–12 h (1·76 [1·18–2·62]; pinteraction=0·0087). Interpretation These findings strengthen the evidence for benefit of endovascular thrombectomy in patients with evidence of reversible cerebral ischaemia across the 6–24 h time window and are relevant to clinical practice. Our findings suggest that in these patients, thrombectomy should not be withheld on the basis of mode of presentation or of the point in time of presentation within the 6–24 h time window. Funding Stryker Neurovascular.